At a glance
Effects
- Lean muscle growth: Potent promotion of protein synthesis and nitrogen retention drives substantial hypertrophy with minimal water retention, producing a hard, dense muscular appearance [2][5].
- Strength gains: Elevated androgen receptor activation and IGF-1 output consistently translate to significant strength increases [5][8].
- Fat loss / body recomposition: Enhanced nutrient utilisation and IGF-1-mediated mobilisation of stored fat contribute to a leaner physique even during caloric maintenance [2][7].
- Anti-catabolism: Suppresses muscle breakdown and preserves lean tissue during caloric deficits [4][8].
- Improved oxygen transport: Stimulates erythropoiesis, increasing red blood cell count and muscular endurance [8].
- No oestrogenic side-effects (from compound itself): Trenbolone does not aromatise, so it does not directly cause oestrogen-driven water retention or gynecomastia from its own conversion; however, testosterone used as a base in the same cycle will still aromatise [7].
Anabolic-androgenic steroid (19-nor / nandrolone group)
~8–14 days (sources vary; 8 days per structural literature, ~14 days per pharmacological characterisation)
Intramuscular injection only
Schedule III controlled substance
Trenbolone and metabolites detectable in urine; banned in- and out-of-competition by WADA
About Trenbolone Hexahydrobenzylcarbonate
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Trenbolone Hexahydrobenzylcarbonate (brand name Parabolan / Hexabolan) is a synthetic, injectable anabolic-androgenic steroid (AAS) of the nandrolone family, existing as the long-acting C17β hexahydrobenzylcarbonate ester prodrug of trenbolone [1][2]. It was the only trenbolone compound ever approved for human use, briefly marketed in France from 1980 until voluntarily discontinued by its manufacturer in 1997, and is no longer prescribed anywhere [1][3].
How it works
After intramuscular injection, plasma esterases cleave the hexahydrobenzylcarbonate ester, releasing free trenbolone into circulation [4]. Trenbolone binds androgen receptors with approximately three times the affinity of testosterone [5][6], driving potent increases in protein synthesis, nitrogen retention, and muscle hypertrophy. Unlike testosterone, trenbolone does not undergo aromatisation to oestrogen and does not convert to the more potent androgenic metabolite dihydrotestosterone (DHT), yet still exerts powerful androgenic effects directly at the receptor [4][7]. It also raises IGF-1 levels and enhances red blood cell production [8].
Risks & side effects
Most important: Trenbolone carries serious cardiovascular risk: AAS users have been shown to face a three-fold higher risk of acute myocardial infarction, a nearly nine-fold increased risk of cardiomyopathy, and elevated risk of venous thromboembolism and arrhythmias compared to non-users [6]. Trenbolone is also associated with severe and largely irreversible suppression of the hypothalamic-pituitary-gonadal (HPG) axis, with neuropsychiatric effects including aggression, insomnia, and anxiety documented in the peer-reviewed literature [7][9].
Common
- Severe suppression of endogenous testosterone production (HPG axis shutdown) [7]
- Night sweats and insomnia [9]
- Erectile dysfunction and reduced libido [7][9]
- Elevated aggression and anxiety [9][10]
- Acne and oily skin [6]
- Excessive body hair growth [6]
- Trenbolone cough (transient coughing fit post-injection, mechanism not fully established) [9]
- Orange discolouration of urine (harmless chromophore effect) [9]
- Injection-site inflammation, muscle adhesions [6]
- 'Tren cough' — violent coughing fit immediately post-injection [1]
Serious
- Adverse lipid profile: markedly reduced HDL, elevated LDL, increasing atherosclerosis risk [6][11]
- Hypertension and left ventricular hypertrophy [6][11]
- Cardiac arrhythmia [6]
- Polycythaemia (excess red blood cells) and thrombosis [11]
- Elevated prolactin levels — may cause gynecomastia, reduced libido, and mood changes in men [7]
- Potential nephrotoxicity (kidney damage observed in animal studies) [5]
- Severe hormonal imbalance if post-cycle therapy (PCT) is omitted [3]
- Immunosuppressive activity [9]
Rare
- Myocardial infarction (case reported in a 23-year-old trenbolone user) [11]
- Dilated cardiomyopathy and heart failure [6]
- Neurodegeneration (demonstrated in animal studies; human risk not fully quantified) [10]
- Genotoxic effects at low concentrations (in vitro / animal evidence) [10]
- Injection-site necrosis [6]
- Reproductive toxicity (animal studies) [10]
Safety & harm reduction
- Women who are pregnant or may become pregnant (virilisation and reproductive toxicity) [10]
- Anyone with pre-existing cardiovascular disease, hypertension, or cardiomyopathy [6][11]
- Individuals with kidney or liver disease [5]
- Anyone under 18 years of age
- Individuals with a history of prostate or breast cancer (androgen-sensitive tumours) [11]
- Competitive athletes subject to WADA or any recognised anti-doping authority [12]
- Full lipid panel (HDL, LDL, total cholesterol, triglycerides) before, during, and after cycle [11]
- Blood pressure monitoring throughout use [6]
- Full blood count / haematocrit to detect polycythaemia [11]
- Serum testosterone, LH, FSH before starting and after PCT to confirm HPG axis recovery [7]
- Prolactin levels (trenbolone can raise prolactin) [7]
- Kidney function markers (creatinine, eGFR) [5]
- Liver enzymes (ALT, AST) — trenbolone is hepatically metabolised [4]
- Cardiac evaluation (ECG) for long-term or heavy users [6]
- Anticoagulants (warfarin, heparin): AAS increase thrombotic risk and may alter anticoagulant effect [11]
- Insulin / oral hypoglycaemics: AAS alter glucose metabolism unpredictably
- Other AAS or androgens: additive cardiovascular, lipid, and suppressive effects [6]
- Aromatase inhibitors (Aromasin, Arimidex): often co-administered when stacked with a testosterone base to manage oestrogen from that base [3]
- Dopaminergic agents (cabergoline): sometimes used to manage trenbolone-raised prolactin [7]
- Testosterone base: trenbolone profoundly suppresses endogenous testosterone; co-administration of exogenous testosterone is strongly advised to avoid androgen deficiency symptoms [3]
- Post-cycle therapy (PCT) is mandatory after cycle completion — commonly a SERM (tamoxifen 40/40/20/20 mg or clomiphene 50 mg/day for 3–4 weeks) to restart HPG axis [3]
- For a hex-ester cycle, PCT should begin approximately 3 weeks after the last injection to account for the long ester clearance [3]
- Prolactin management: cabergoline or other dopamine agonists may be needed if prolactin-related symptoms emerge [7]
- Lipid support: omega-3 supplementation and cardiovascular exercise may partially mitigate cholesterol impact (evidence limited) [11]
- Cycle length: community-reported standard cycles are 6–12 weeks; longer cycles substantially increase risk of side effects [3]
Dosage context
No currently approved human prescription exists. The only historical clinical dosage was one ampoule (76 mg, corresponding to approximately 50 mg trenbolone base) every 10 days, as used by the original French manufacturer Negma [1]. Community-reported performance dosages of 100–300 mg per week are widely cited, with 200 mg/week described as a common starting point for experienced users; cycles typically run 6–12 weeks [3]. These figures are not medically sanctioned and are presented for harm-reduction context only. Given the compound's potency and risk profile, lower doses for shorter durations carry fewer risks. Trenbolone is not appropriate for beginners [3].
Sources
- 1.Wikipedia — Trenbolone hexahydrobenzylcarbonate
- 2.Grokipedia — Trenbolone hexahydrobenzylcarbonate pharmacology
- 3.Actiza Pharma — Trenbolone Hexahydrobenzylcarbonate Injection monograph
- 4.Wikipedia — Trenbolone (mechanism / metabolism)
- 5.ResearchGate — Structural studies of Trenbolone esters (half-life / AR affinity)
- 6.ResearchGate — Adverse effects of trenbolone: structured review of case reports
- 7.Clerkenwell-London — Parabolan effects, dosage and cycle guide
- 8.Swolverine — Tren 101: Understanding Trenbolone
- 9.PMC — Medicinal Use of Testosterone and Related Steroids Revisited
- 10.ScienceDirect — Trenbolone, psychological distress, and aggression (2024)
- 11.PMC — Myocardial infarction due to Trenbolone Acetate: case report
- 12.Swolverine — Trenbolone controlled substance schedule / WADA status
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Trenbolone Hexahydrobenzylcarbonate· 4 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
EVO | vial | 100 mg/ml | 10 ml | 54,90 € | ★€0.055/mg |
GenericSelected | vial | 75 mg/ml | 10 ml | 64,90 € | €0.087/mg |
Generic | vial | 150 mg/ml | 10 ml | 104,99 € | €0.070/mg |
Driada | vial | 75 mg/ml | 10 ml | 119,99 € | €0.160/mg |
Substance reviews(1)
Independent reviews of this compound from the wider market — about the substance, not our delivery.
- ★★★★★28 days ago
Great vendor. Good communication. Will order again thanks.